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Zika virus (ZIKV) is a mosquito borne flavivirus that can trigger Guillian-Barre syndrome 
and cause congenital brain defects in pregnancy due to its infection and persistence in both 
adult and fetal neural cells. Currently there is no treatment available for ZIKV. Through a 
chemical screen, we have identified hippeastrine as a drug candidate that can block and clear 
ZIKV infection in vitro in human cortical neural progenitor cells (hNPCs) and in adult mouse 
brains. However, hippeastrine only exhibits moderate potency and its mechanism of action is 
unknown. Therefore, we aim to enhance hippeastrine’s anti-ZIKV activity through medicinal 
chemistry and better understand its mechanism against ZIKV.   
Methods 
 To enhance the potency, we modified specific functional groups on hippeastrine through 
synthetic chemistry. The reactions utilized included the esterification of the alcohol, saturation of 
the alkene, opening of the cyclic acetal and changing the lactone to a lactam. These 
hippeastrine derivates were then tested for their activity in hNPCs.  
Results 
 We have synthesized ten analogues and preliminary testing has shown that 
modifications at the alcohol have significantly increased activity. In contrast, reduction of the 
double bond in hippeastrine completely abolishes its anti-ZIKV activity. Based on this structure 
activity relationship, a photoaffinity labeling group was attached at the alcohol to the saturated 
or unsaturated hippeastrine for use in cellular pulldown assays to identify hippeastrine’s 
tinteracting proteins.  
Conclusions 
 Based on the results we have shown that it is possible to modify the anti-ZIKV activity of 
hippeastrine. The best improvement was a 5-fold increase in potency. These results along with 
the synthesis of photoaffinity labelled hippeastrine derivatives will allow for further enhancement 
of potency and elucidation of hippeastrine’s role in blockade and clearance of ZIKV infection.   
 
1. Introduction 
Zika virus (ZIKV) is an Aedes mosquito borne flavivirus first discovered in Uganda in 
19471-2. Human infection with ZIKV was identified as early as 1952 and the virus spread 
throughout Africa and Asia, with the infection associated with mild disease. The first major 
outbreak of ZIKV occurred in the Island of Yap in 2007. In most of these cases, over 80% of the 
infected patients were asymptomatic.3 However, the ZIKV associated neurological complications 
such as onset of Guillian-Barre syndrome in adults and microcephaly in newborns, weren’t 
realized until the 2015 outbreak in Brazil.1-2 Specifically, there was 20-fold increase in 
microcephaly reported during the outbreak compared to pre-ZIKV prevalence.1 Case-control 
studies further confirmed this correlation.4 Due to these findings and increased transmission, by 
February 2016 the World Health Organization (WHO) had declared the outbreak as a Public 
Health Emergency of International Concern.1  
 The neurological complications are the result of the predominance and persistence of 
ZIKV infection in neural cells. ZIKV also demonstrates the ability to undergo intrauterine transfer 
into the placental and fetal brain cells from an infected mother, which can lead to the 
development of microcephaly.5 Specifically, ZIKV isolates from the 2015 outbreak were shown 
to infect in the fetal human neural progenitor cells (hNPCs), and aside from the initial cytopathic 
effects, persist in the cells, evading immune detection and elimination. This persistence is linked 
to continued replication and ultimately neuronal cell death.6 Despite this knowledge, there is no 
current treatment to block ZIKV infection.  
 With no approved medications to treat ZIKV infection, current treatment strategies are 
directed towards symptom management.3 Further emphasis has been placed on infection 
transmission prevention measures1, especially in light of the ability of ZIKV to persist in bodily 
fluids.7 This prevention, however, cannot prevent the ZIKV-induced adult and fetal neurological 
complications, and all treatment measures are supportive.6 
 With the pressing need for a therapeutic option, Xu et al. performed a high-throughput 
screen of 6000 currently approved drugs and drug candidates to measures their ability to either 
suppress ZIKV infection or prevent further replication.8 The initial compounds were chosen for 
their ability to inhibit caspase-3, based on the finding that caspase-3 activity increased after 
ZIKV infection. Their screen provided two classes of drugs that protected against cell death and 
inhibited ZIKV replication: neuroprotective and antiviral agents, respectively. Furthermore, when 
the two types of agents were combined, they showed synergistic effects by preventing cell 
death while allowing cells to recover from ZIKV infection by stalling replication.8 However, while 
the drugs were effective in reducing viral load, they did not demonstrate the ability to clear the 
infection from host cells.8 This result is problematic because ZIKV persistence could still lead to 
neural complications and future transmission.6  Specifically, it has been reported that even if 
ZIKV was limited to 1% of the initial viral load, it could replicate and induce cell death later.9   
 In order to identify a possible drug that can block and clear ZIKV infection, Zhou et al 
screened over 1000 drug candidates in ZIKV infected hNPCs.9 This screen led to the discovery 
that hippeastrine, a naturally occurring compound derived from the amaryllidacease family plant 
Lycoris radiata, could block and eliminate ZIKV infection at an EC50 of 5.5 µM, a promising 
measure of its potency in vitro. Hippeastrine was also studied in vivo in adult mouse brains and 
in human fetal forebrain organoids, showing similar results. In the latter, hippeastrine showed 
the ability to “rescue” the infected organoids, both preventing ZIKV activity and restoring ZIKV 
induced structural defects that are associated with microcephaly pathologies.9 These findings 
demonstrate the promise of hippeastrine as a drug candidate for ZIKV treatment, given its ability 
to treat ZIKV infection during multiple stages of its pathogenicity.  
 It was also determined in this study that hippeastrine clears ZIKV infection with no effect 
on the cell identity and differentiation capacity after pre-existing entry of the ZIKV.9 However, the 
exact mechanism of action of hippeastrine employs to mediate this clearance is unknown. Also, 
hippeastrine only demonstrates moderate potency. Consequently, the overall objective of this 
project is to further improve hippeasterine’s potency through synthetic chemistry and identify its 
mechanism of action in the infected cells in order to optimize it as a drug candidate for the 













2.1 Synthesis of Derivatives of Hippeastrine to Increase its Anti-ZIKV Activity 
The hippeastrine derivatives to synthesize 
were chosen based on four modifiable functional 
groups of hippeastrine (HH): the lactone, alcohol, 
alkene and acetal. The structure of hippeastrine 
and the functional groups can be visualized in 
Figure 1.  Furthermore, diazirine containing 
photoaffinity linkers were attached with 
hippeastrine to allow for future use in assays. The 
derivatives were confirmed via 1H NMR and mass 
spectrometry.  
2.1.1 Modifications at the alcohol 
 On the free alcohol, two reactions were 
performed. The first set of reactions involved the 
acylation of the free alcohol.  
(1) 2-acetylhippeastrine 
To 2 mg HH in 250 µL of pyridine, 
250 µL of acetic anhydride was added. 
After 4 hours of stirring, the solvent was 
evaporated and the residue purified by column chromatography with a gradient from 0-
5% MeOH in dichloromethane (DCM), yielding 1.8 mg as a white solid.  
(2) 2-butylhippeastrine 
To a solution of 2 mg of HH (1 equiv.) in 1 mL of anhydrous DCM, NEt3 (2.5 
equiv.) and butyl chloride (1.5 equiv.) were added. The reaction was allowed to stir for 
12 hours, before the solvent was evaporated and the residue purified by column 
chromatography with a gradient from 0-5% MeOH in DCM, yielding 1.6 mg as a white 
solid.   
(3) 2-heptanoate-hippeastrine  
 Heptanoic acid (1.5 equiv.), N,N’-Dicyclohexylcarbodiimide (DCC) (1.5 equiv.) 
and 4-dimethylaminopyridine (DMAP) (0.1 equiv.) were stirred in DCM at room 
temperature for 30 minutes. To this solution, 2 mg HH dissolved in 0.5 mL of DCM was 
added and allowed to stir for 12 hours. The reaction mixture was then evaporated and 
purified by column chromatography with a gradient from 0-5% MeOH in DCM, yielding 
1.1 mg as a white solid.   
(4) 2-benzoate-hippeastrine 
To a solution of 2 mg of HH in anhydrous DCM, trimethylamine NEt3 (2.5 equiv.) 
and benzoyl chloride (1.5 equiv.) were added. The reaction was allowed to stir for 12 
hours, before the solvent was evaporated and the residue purified by column 
chromatography with a gradient from 0-5% MeOH in DCM, yielding 1.3 mg as a white 
solid.   
(5) 2-(2-(3-(But-3-yn-1-yl)-3H-diazirin-3-yl)acetyl hippeastrine 
 2-(3-(But-3-yn-1-yl)-3H-diazirin-3-yl)acetic acid was prepared based on the 
reference by Kleiner et al5. 2-(3-(But-3-yn-1-yl)-3H-diazirin-3-yl)acetic acid(1.5 equiv.), 
DCC (1.5 equiv.) and DMAP (0.1 equiv.) were stirred in DCM at room temperature for 30 
minutes. To this solution, 2 mg HH dissolved in 0.5 mL of DCM was added and allowed 
to stir for 12 hours in the dark. The reaction mixture was then evaporated and purified by 
 
Figure 1. Hippeastrine molecule. A-D 
denote the four major functional 
groups: (A) lactone, (B) alcohol, (C) 





column chromatography with a gradient from 0-5% MeOH in DCM, yielding 0.8 mg as a 
white solid.   
(6) 2-methyl hippeastrine  
 To a solution of NaH (1.1 equiv.) in dry THF at 0 °C, 2 mg of HH was added and 
stirred for 30 minutes. Methyl iodide (1.5 equiv.) was added and the reaction was heated 
and refluxed for 12 hours. The mixture was then cooled and the solvent removed by 
evaporation. The crude product was purified by column chromatography with gradient 
from 0-5% MeOH in DCM, yielding 1.3 mg as a white solid.   
2.1.2 Modification at the acetal 
 (7) 8,9-Norhippeastrine 
 To a solution of 2 mg HH in dry DCM, at 0 °C, 1 M BBr3 in DCM (1.5 equiv.) was 
added dropwise. The reaction mixture was stirred for five hours and then the solvent 
removed by evaporation. The crude product was purified by column chromatography 
with a gradient from 0-5% MeOH in DCM, yielding 1.1 mg as a brown oil.  
2.1.3 Modifications at the alkene 
 (8) 3,4R-Dihydrohippeastrine 
 To a solution of 2 mg of HH in 1 ml of methanol, a catalytic amount of Pd/C was 
added.  Air was evacuated from the reaction flask and cycled with hydrogen gas three 
times before remaining under hydrogen gas for 12 hours. The resulting solution was 
filtered through Celite and washed five times before the solvent was evaporated 
resulting in 2 mg of white solid. 
 (9) 2-acetyl-(3,4R-Dihydrohippeastrine) 
To 2 mg of 8 in 250 µL of pyridine, 250 µL of acetic anhydride was added. After 4 
hours of stirring, the solvent was evaporated and the residue purified by column 
chromatography with a gradient from 0-5% MeOH in DCM, yielding 1.6 mg as a white 
solid.  
 (10) ) 2-(2-(3-(But-3-yn-1-yl)-3H-diazirin-3-yl)acetyl-(3,4R-Dihydrohippeastrine) 
 2-(3-(But-3-yn-1-yl)-3H-diazirin-3-yl)acetic acid was prepared based on the 
reference by Kleiner et al5. 2-(3-(But-3-yn-1-yl)-3H-diazirin-3-yl)acetic acid(1.5 equiv.), 
DCC (1.5 equiv.) and DMAP (0.1 equiv.) were stirred in DCM at room temperature for 30 
minutes. To this solution, 2 mg of 8 was dissolved in 0.5 mL of DCM was added and 
allowed to stir for 12 hours in the dark. The reaction mixture was then evaporated and 
purified by column chromatography with a gradient from 0-5% MeOH in DCM, yielding 
0.9 mg as a white solid.   
2.2 Determination of Hippeastrine Derivatives Anti-ZIKV Activity in hNPCs 
To determine the anti-ZIKV activity, the hippeastrine derivatives were initially dissolved 
in DMSO to make a 50 µM stock solution, and then diluted to ten different concentrations: 50, 
25, 10, 5, 2.5, 1, 0.5, 0.25, 0.1, and 0.05 µM. These ten concentrations were tested in the ZIKV-
infected hNPCs to determine percent ZIKV expression at each dose. Using the resulting dose-









3.1 Synthesis of Hippeastrine Derivatives to Increase Anti-ZIKV Activity 















Figure 2. Scheme denoting the preparation and structures of the hippeastrine derivatives 
synthesized. 
3.2 Determination of Hippeastrine Derivatives Anti-ZIKV Activity in hNPCs 
For the ten synthesized derivatives, the IC50 was determined along with their calculated 
ClogP and molecular weight as shown in Table 1.  
 
Table 1. Physiochemical descriptors and in vitro anti-ZIKV activity as denoted by IC50 in 
hNPCs. 
Compound MW (AU) ClogP IC50 (µM) 
HH 315.33 1.18 5.5 
1 357.36 2.08 1.2 
2 399.44 3.51 25.4 
3 441.52 5.10 25.2 
4 419.43 3.94 No Activity 
5 449.46 2.56 38.5 
6 329.35 1.78 No Activity 
7 303.31 0.43 6.8 
8 317.34 1.46 No Activity 
9 358.38 2.36 No Activity 
10 451.48 2.84 No Activity 
 
From this data, one hippeastrine derivative, the product of the acylation of the free 
alcohol with an acetate, 1, was found to have increased anti-ZIKV activity. There was a five-fold 
increase in potency compared to hippeastrine. However, further acylation reactions with longer 
acyl chains of four or seven carbons, 2 and 3 respectively, or a phenyl functional group, 4, had 
detrimental effects on the anti-ZIKV activity. 
Modifications on the other functional groups on hippeastrine also altered its anti-ZIKV 
activity. The methylation of the free alcohol ,6, saturation of the double bond, 8, and subsequent 
modification on the saturated hippeastrine, 9 and 10, rendered the molecule inactive. The 
deprotection of the acetal group, 7, resulted in a minimal decrease in potency. 
The synthesis of 5 and 10, represent the hippeastrine with photoaffinity linkers to be 
utilized when determining interacting proteins. The hippeastrine with photoaffinity linker 
demonstrated anti-ZIKV activity, though with diminished potency.  On the other hand, 10, the 
saturated hippeastine with photoaffinity linker, did not exhibit anti-ZIKV activity. Because of the 
small modification compared to HH, analog 10 works as an ideal control compound to study 
HH’s biological functions. 
 
4. Discussion 
From the results, we have demonstrated the ability to modify the anti-ZIKV activity of 
hippeastrine. These initial modifications have shed some light on the structure activity 
relationship of hippeastrine. The increase in potency with the addition of the acetate on the free 
alcohol could be associated with cellular permeability based on the increased lipophilicity and 
labile nature of the bond. However, while the addition of longer carbon chains should contribute 
to increased cellular permeability, this was not seen in the activity data. This finding could be 
attributed to a binding site or channel that is limited sterically. Also, the loss of activity 
associated with the saturation of the alkene also alludes to the importance of the conformation 
of hippeastrine.  
However, with only knowledge of structural changes and resulting activity, a definitive 
mechanism of action for how hippeastrine acts in the cell cannot be elucidated. In order to 
determine the mechanism of action, the specific interacting proteins of hippeastrine must be 
identified, which is a limitation of this study. However, both an active and inactive photoaffinity 
labeled hippeastrine were synthesized and tested in this study to utilize in future cellular pull-
down assays to determine the interacting proteins.  
This study has shown the ability to enhance the anti-ZIKV activity of hippeastrine. With 
other modifications, such as the conversion of the lactone to lactam, and cellular pull-down 
assays yet to be completed, there is promise for the site directed determination of a 
hippeastrine derivative with further enhanced potency.  
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Dissemination Plan 
The hope is to both present and publish the research. However, a couple steps need to 
completed before meetings and journals for publication are considered. First, the cellular pull-
down assays to determine interacting proteins must be completed. Second, the synthesis of the 
lactone to lactam hippeastrine derivative will demonstrate a significant alteration of 
hippeastrine’s structure and should be completed to determine its effect on anti-ZIKV activity. 
Therefore, the focus of the hopeful publication will have a much broader focus on the alterations 
and MOA of hippeastrine and their implications in the treatment of ZIKV.  
 
Challenges Encountered 
The main challenge encountered in the completion of this project was the time to be devoted to 
bench work when also taking the classes in the PharmD curriculum. This was especially the 
case during synthesis and purification of the molecules, and certain timed or multi-step 
syntheses.  
 
